Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of BF-Methyldopa vs Metopa in Healthy Volunteers
NCT03210025Phase 1Completed
- Sponsor
- Bright Future Pharmaceutical Laboratories Limited
- Start
- Sep 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of methyldopa in hypertension (HTN) (2 arms), sponsored by Bright Future Pharmaceutical Laboratories Limited. Primary endpoints: Maximum Plasma Concentration at 24 hours and Area Under the Curve at 24 hours. Started Sep 2017; status: completed.
02
Drugs
methyldopa
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03210025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03210025.